Heptares and NYU to discover GPCRs to treat cancer

The Heptares Therapeutics Ltd. subsidiary of Sosei Group Corp. (Tokyo:4565) partnered with the New York University School of Medicine (New York, N.Y.) to discover molecules that selectively modulate an undisclosed GPCR that the partners say is implicated in the formation and progression of glioblastoma multiforme...